Cellosaurus

PubMed=3856042; DOI=10.1093/jnci/74.2.283
Herlyn M., Balaban G., Bennicelli J.L., Guerry D. IV, Halaban R., Herlyn D., Elder D.E., Maul G.G., Steplewski Z., Nowell P.C., Clark W.H., Koprowski H.
Primary melanoma cells of the vertical growth phase: similarities to metastatic cells.
J. Natl. Cancer Inst. 74:283-289(1985)

PubMed=4053039
Herlyn M., Thurin J., Balaban G., Bennicelli J.L., Herlyn D., Elder D.E., Bondi E., Guerry D. IV, Nowell P.C., Clark W.H., Koprowski H.
Characteristics of cultured human melanocytes isolated from different stages of tumor progression.
Cancer Res. 45:5670-5676(1985)

PubMed=3020539; DOI=10.1073/pnas.83.19.7197
Westermark B., Johnsson A., Paulsson Y., Betsholtz C., Heldin C.-H., Herlyn M., Rodeck U., Koprowski H.
Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor.
Proc. Natl. Acad. Sci. U.S.A. 83:7197-7200(1986)

PubMed=2253310; DOI=10.1007/BF00046337
Herlyn M.
Human melanoma: development and progression.
Cancer Metastasis Rev. 9:101-112(1990)

PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x
Tsao H., Goel V., Wu H., Yang G., Haluska F.G.
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
J. Invest. Dermatol. 122:337-341(2004)

PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x
Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R., Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D., Dummer R.
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.
Pigment Cell Res. 19:290-302(2006)

PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235
Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R., Muthusamy V., King A.J., Flaherty K.T., Bosenberg M., Herlyn M., Nathanson K.L.
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
Cancer Res. 68:5743-5752(2008)